Evidence map›Paper›PMID 40366390›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.

Rajiv Ranjit Nair, Aira Sarkar, Pooja Hariharan, Kathleen L Gabrielson, Tony Wu, Chang Liu, Anjali Sharma, Wathsala Liyanage, Zaver M Bhujwalla, Marie-France Penet Vidaver and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rajiv Ranjit Nair *Chemical and Biomolecular Engineering (ChemBE), Institute for NanoBioTechnology (INBT), Johns Hopkins University, Baltimore, MD, USA.
Aira Sarkar *Chemical and Biomolecular Engineering (ChemBE), Institute for NanoBioTechnology (INBT), Johns Hopkins University, Baltimore, MD, USA.
Pooja HariharanChemical and Biomolecular Engineering (ChemBE), Institute for NanoBioTechnology (INBT), Johns Hopkins University, Baltimore, MD, USA.
Kathleen L GabrielsonMolecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, USA.
Tony WuCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
Chang LiuCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
Anjali SharmaCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
Wathsala LiyanageCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
Zaver M BhujwallaRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Marie-France Penet VidaverRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
Rangaramanujam M KannanCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA.
Stavroula SofouChemical and Biomolecular Engineering (ChemBE), Institute for NanoBioTechnology (INBT), Johns Hopkins University, Baltimore, MD, USA. ssofou1@jhu.edu.ORCID 0000-0003-1735-326X

Funding

Hartwell Foundation N/AUncle Kory Foundation N/A
6 · The paper itself

Abstract

purposeThe poor prognosis of glioblastoma is mostly due to the relatively low tumor vascular permeability to therapeutics, the tumor's vicinity to the brain, that limits treatment aggressiveness, and/or drug resistance.

methodsIn this study, the efficacy of systemically injected actinium-225 dendrimer-radioconjugates was evaluated in an immune-competent orthotopic GL261-C57BL/6 mouse model after administration of low-dose, standard-of-care temozolomide, that selectively increased the tumor vascular permeability to dendrimer-radioconjugates. Alpha-particles' short range in tissue combined with the dendrimers' selective uptake by glioblastomas, could limit the irradiation of the neighboring brain, while the complex double-strand DNA breaks caused by α-particles were expected to be largely impervious to resistance by cancer cells.

resultsOn mice bearing 9.7 ± 5.7mm

conclusionsThis study demonstrates the potential and safety of actinium-225 dendrimer-radioconjugates as a systemic α-particle radiotherapy for glioblastoma enhanced by low-dose temozolomide.

Indexed as

ActiniumAlpha ParticlesBrain NeoplasmsCapillary PermeabilityDacarbazineDendrimersGlioblastomaTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceMice, Inbred C57BLTemozolomideTreatment OutcomeActiniumActinium-225DacarbazineDendrimersTemozolomideActinium-225 alpha-particle radionuclide therapyDendrimer-radioconjugatesGlioblastomaSpheroidsTemozolomideTumor-associated macrophages

Identifiers

PMID40366390

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.